Variable | Value |
---|---|
Number of patients | 214 |
Age (years) | 41.4 ± 12.6 |
Sex (male, %) | 66.4% |
Mean arterial pressure (mmHg) | 99 ± 15 |
Serum creatinine (mg/dL) | 2.02 ± 1.57 |
eGFR (ml/min/1.73m2) | 55.2 ± 31.5 |
CKD stage (%) | |
• G1 | 15.8% |
• G2 | 24.8% |
• G3 | 34.1% |
• G4 | 19.2% |
• G5 | 6.1% |
Albumin (g/dL) | 4.07 ± 0.63 |
Serum IgA (mg/dL) | 351 ± 153 |
Increased serum IgA (% pf pts.) | 27.9% |
Serum C3 (mg/dL) | 116 ± 24 |
Decreased serum C3 (% of pts.) | 12.9% |
IgA/C3 ratio | 3.18 ± 1.62 |
Hematuria (cells/µL) | 35 (14–84) |
Hematuria (% of pts) | |
• Absent | 37.2% |
• Mild | 28% |
• Moderate | 15.5% |
• Severe | 19.3% |
24-h proteinuria (g/24 h) | 1.5 (0.8–3.25) |
24-h proteinuria (% of pts) | |
• Proteinuria < 0.75 g/24 h (%) | 22.9% |
• Proteinuria 0.75–3.5 g/24 h (%) | 54.2% |
• Proteinuria > 3.5 g/24 h (%) | 22.9% |
Treatment | |
• RAAS inhibitors (%) | 88% |
• Corticosteroids monotherapy (%) | 46.2% |
• Corticosteroids ± other immunosuppressive agent (%) | 25.5% |
Outcome | |
• Doubling of serum creatinine (%) | 18.2% |
• ESRD (%) | 24.8% |
• Combined endpoint (%) | 29% |
Follow-up (months) | 49.1 (17.3–86.2) |